Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia

2020 ◽  
Vol 21 (14) ◽  
pp. 1675-1684
Author(s):  
Laura D’Erasmo ◽  
Antonio Gallo ◽  
Alessia Di Costanzo ◽  
Eric Bruckert ◽  
Marcello Arca
2021 ◽  
Vol 331 ◽  
pp. e293
Author(s):  
R.S. Rosenson ◽  
D. Gaudet ◽  
C.M. Ballantyne ◽  
S.J. Baum ◽  
J. Bergeron ◽  
...  

2014 ◽  
Vol 99 (5) ◽  
pp. 1525-1530 ◽  
Author(s):  
Hiroyasu Yamamoto ◽  
Minoru Tanaka ◽  
Satomi Yoshiga ◽  
Tohru Funahashi ◽  
Iichiro Shimomura ◽  
...  

2001 ◽  
Vol 2 (2) ◽  
pp. 141
Author(s):  
P. Fornengo ◽  
A. Bruno ◽  
R. Gambino ◽  
M. Cassader ◽  
G. Pagano

2017 ◽  
Vol 102 (5) ◽  
pp. 1454-1457 ◽  
Author(s):  
Masako Ueda ◽  
Richard L. Dunbar ◽  
Anna Wolska ◽  
Tracey U. Sikora ◽  
Maria del Rosario Escobar ◽  
...  

Abstract Context: Familial chylomicronemia syndrome (FCS) is a rare heritable disorder associated with severe hypertriglyceridemia and recurrent pancreatitis. Lipoprotein lipase deficiency and apolipoprotein C-II deficiency are two well-characterized autosomal recessive causes of FCS, and three other genes have been described to cause FCS. Because therapeutic approaches can vary according to the underlying etiology, it is important to establish the molecular etiology of FCS. Case Description: A man originally from North Africa was referred to the University of Pennsylvania Lipid Clinic for severe hypertriglyceridemia and recurrent pancreatitis, consistent with the clinical diagnosis of FCS. Molecular analyses of FCS-associated genes revealed a homozygous missense variant R72T in APOC2. Molecular modeling of the variant predicted that the apolipoprotein C-II R72T peptide has reduced lipid binding affinity. In vitro studies of the patient’s plasma confirmed the lack of functional apoC-II activity. Moreover, the apoC-II protein was undetectable in the patient’s plasma, quantitatively as well as qualitatively. Conclusions: We identified a missense APOC2 variant causing apoC-II deficiency in a patient with severe hypertriglyceridemia and recurrent pancreatitis. Beyond dietary management and usual pharmacologic therapies, an apoC-II mimetic peptide may become an optional therapy in patients with apoC-II deficiency in the future.


2015 ◽  
Vol 373 (5) ◽  
pp. 438-447 ◽  
Author(s):  
Daniel Gaudet ◽  
Veronica J. Alexander ◽  
Brenda F. Baker ◽  
Diane Brisson ◽  
Karine Tremblay ◽  
...  

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Veronica Alexander ◽  
Diane Brisson ◽  
JoAnn Flaim ◽  
Steve Hughes ◽  
Walter Singleton ◽  
...  

Background: Apolipoprotein C-III (apoC-III), a CV risk factor, plays a pivotal role in regulating plasma triglyceride (TG) levels. Elevated TG and its nonesterified fatty acid (NEFA) derivatives are associated with insulin resistance and type 2 diabetes. ISIS-APOCIII Rx selectively inhibits apoC-III protein synthesis in the liver and studies show it may improve insulin sensitivity in patients with type 2 diabetes. Treatment with ISIS-APOCIII Rx results in significant dose-dependent decreases in apoC-III and TG levels (Table) in patients with severe hypertriglyceridemia (SHTG) as monotherapy or add on to a stable dose of fibrate. The present study assessed the potential resulting change in NEFA levels in these patients. Methods: Adult patients with SHTG treated or untreated with fibrate were enrolled in a double-blind Phase 2 study to receive ISIS-APOCIII Rx (up to 300 mg) or placebo as weekly SC injections for 13 weeks. Baseline and end-of-treatment fasting serum samples were analyzed for NEFA levels. Results: Results show significant reductions in NEFA levels in line with reductions in TG levels at the 300 mg/week dose (the Phase 3 dose) of ISIS-APOCIII Rx (Table). ISIS-APOCIII Rx was generally safe and well tolerated. There were no clinically meaningful changes in liver tests or other laboratory values. Conclusions: Treatment with ISIS-APOCIII Rx reduces NEFA levels together with decreases in TG in patients with treated or untreated SHTG suggesting the potential for improvement in peripheral insulin sensitivity in these patients.


Author(s):  
Gulay Simsek Bagir ◽  
Okan Sefa Bakiner ◽  
Filiz Eksi Haydardedeoglu ◽  
Filiz Araz ◽  
Melek Eda Ertorer ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document